Your Daily Women's Health Briefing

2026 RISE UP Conference Challenges Standardized Mammography Screening

• Daré Bioscience, a health biotech company, announced on August 31, 2026, that it received a new notice of award from the National Institutes of Health (NIH) for approximately $908,000. This funding will advance its DARE-PTB2 program, an early-stage investigational program focused on developing a new therapeutic approach for the prevention of preterm birth, a leading cause of infant morbidity and mortality worldwide with no FDA-approved treatments.

  Biospace

• The 2026 RISE UP for Breast Cancer and Women's Health Conference, held on August 30, 2026, showcased early outcomes from the PRSONAL randomized clinical trial. This trial is challenging the long-standing practice of standardized mammography screening by investigating whether a woman's individual breast cancer risk can safely determine her screening frequency and if communicating this risk does more psychological good than harm.

  Bioengineer

• On August 31, 2026, Delaware Attorney General Kathy Jennings, as part of a coalition of 23 states, filed a lawsuit in the U.S. District Court for the District of Maryland. The suit aims to block new federal policies that threaten to cut Title X family planning funding by penalizing states and providers who do not conform to the administration's ideological vision of family planning or abandon non-discrimination initiatives.

  Delaware Gov

• A recent report highlighted that 33 of Arkansas's 75 counties, representing 44% of the state, are classified as maternity care deserts, lacking obstetric care facilities or clinicians. This forces pregnant women to travel an hour or more for routine prenatal appointments and emergency care, a surprising reality in a state that has been named the most "pro-life" in America.

  Washington Post